Innovative Leadership Team

Esperion’s team of industry leaders with proven expertise in understanding cholesterol biosynthesis combines excellence in drug development with superior business skills demonstrating a commitment to delivering patients and physicians with a new oral therapy to reduce LDL-C. Esperion’s team has deep and broad relationships with other industry-leading experts and businesses, enabling us to extend our impact where and when needed.

  • Tim Mayleben

    Tim Mayleben is President and Chief Executive Officer and has been a member of our board of directors since February 2010. Prior to joining Esperion, Tim was President, CEO and a Director at Vericel Corporation, formerly Aastrom Biosciences, Inc. (NASDAQ: VCEL). Previously, Tim was President, Chief Operating Officer and a director of NightHawk Radiology Holdings, Inc. Prior to joining Nighthawk, Tim was the COO of the original Esperion, until its acquisition by Pfizer in 2004. Tim is an advisor to, investor in, and member of the board of directors of several life science companies, including Kaléo Pharma, LOXO Oncology, Marinus Pharmaceuticals, and the Wolverine Venture Fund. Tim earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.

  • Narenda Lalwani, PhD, MBA, FAHA

    Narendra Lalwani is Executive Vice President, Research and Development, and Chief Operating Officer. Prior to joining Esperion, Narendra was Chief Scientific Officer at Cerenis Therapeutics from 2007 to 2014 where he led R&D activities for the company. Previously, Narendra was Vice President of Drug Safety at the original Esperion until its acquisition by Pfizer. Prior to Esperion, Narendra held various positions of increasing responsibility in the Department of Pathology and Experimental Toxicology at Warner-Lambert/Parke-Davis. Narendra is a Fellow of American Heart Association (FAHA) and a diplomate of the American board of Toxicology (DABT). Narendra earned a PhD in Biophysics from the University of Bombay (India) and an MBA from the University of Michigan, Ross School of Business.

  • Mary McGowan, MD

    Mary McGowan is Chief Medical Officer. Prior to joining Esperion, Mary held senior positions in the cardiovascular group at Genzyme/Sanofi. Before moving to industry, Mary spent 20 years as the director of a large lipid disorders clinic in New Hampshire and continues to see patients twice monthly at the Dartmouth Hitchcock Lipid Clinic in Lebanon, NH. Mary has been the primary investigator on many national and international lipid lowering trials, and served as a board member of the National Lipid Association for five years. She was the Chief Medical Officer of the Familial Hypercholesterolemia Foundation and also served on the National Lipid Association’s Expert Panel on Familial Hypercholesterolemia, the New Hampshire Childhood Obesity Expert Panel, and New Hampshire board of the American Heart Association. Mary has authored a variety of articles in peer reviewed journals on lipid metabolism, has written five books for the lay press, including “Heart Fitness for Life” (Oxford University Press) and “50 Ways to Lower Your Cholesterol” (McGraw-Hill), and has served as a reviewer for the Journal of Clinical Lipidology and The New England Journal of Medicine. Mary completed medical school and residency training at the University of Massachusetts Medical Center and a fellowship at Johns Hopkins.

  • Marianne Andreach

    Marianne Andreach is Senior Vice President of Strategic Marketing and Product Planning. Prior to joining Esperion, Marianne was a consultant in the pharmaceutical industry. Previously, she was Senior Director, Business Development and Team Lead, MDCO-216 (ApoA-I Milano) at The Medicines Company. Marianne also worked in Medical Affairs at Pfizer Global R&D, and led Marketing and Product Planning at the original Esperion. Additionally, Marianne has worked in a variety of marketing and product planning roles at Bristol-Myers Squibb and Parke-Davis, including working on the launch teams for both Pravachol and Lipitor, as well as supporting both Plavix and Glucophage. Marianne earned a BA in Biology/History from the College of the Holy Cross.

  • Ashley Hall

    Ashley Hall is Vice President of Global Regulatory Affairs. Prior to joining Esperion, Ashley was Global Regulatory Lead for Cardiovascular at Amgen, and oversaw the regulatory strategy and global filings for the evolocumab program leading to the world’s first approval of a PCSK9 inhibitor for cholesterol lowering. Previously, Ashley was Vice President of Regulatory Affairs at Micromet, which was acquired by Amgen in March of 2012. Prior to joining Micromet, she was Vice President of Regulatory and Clinical Affairs at RevoGenex, and before that, Director of World Wide Regulatory Affairs with the oncology team at MedImmune. Ashley held various roles of increasing responsibility in global Regulatory Affairs at Abraxis BioScience and at La Jolla Pharmaceutical Company. Ashley has also worked in Global Regulatory Policy at Amgen and as a policy intern for Francis Collins at the National Human Genome Institute. Ashley earned her Juris Doctorate at the University of San Diego School of Law and her Bachelors of Science in Biochemistry and Cell Biology at the University of California San Diego.

  • Rick Bartram

    Rick Bartram is Vice President of Finance. Prior to joining Esperion, Rick was Assurance Manager with PricewaterhouseCoopers (PwC) where he held various positions of increasing responsibility over almost eight years with the firm. Rick earned both Master’s and Bachelor’s degrees in accounting from Michigan State University, and is a Certified Public Accountant.